ReviewCNS spectrums2016
Effects of serotonin in the hippocampus: how SSRIs and multimodal antidepressants might regulate pyramidal cell function.
Review in CNS spectrums, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 2 syntheses or guidelines pooled it, 149 citations in OpenAlex.
- Meta-Analysis of Brain Volumetric Abnormalities in Patients with Remitted Major Depressive Disorder.Depression and anxiety · 2024Pooled it
- Neuroprotective Potency of Neolignans inFrontiers in pharmacology · 2022Pooled it
- Effects of SSRI treatment on GABA and glutamate levels in an associative relearning paradigm.NeuroImage · 2021Trial
- Serotonin depletion amplifies distinct human social emotions as a function of individual differences in personality.Translational psychiatry · 2021Trial
- Caffeine reverses sleep deprivation-induced synaptic and social memory deficits via adenosine receptor modulation in the male mouse hippocampal CA2 region.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- A depression-like phenotype is associated with discrete defects in the primary hippocampal circuit.Translational psychiatry · 2026Article
- Ibogalogs induce antiseizure activity in rodents by a mechanism involving 5-HTBiochemical pharmacology · 2026Article
- Lower Plasma Serotonin is Associated with Higher Amyloid Burden, Hippocampal Atrophy, and Cognitive decline in Alzheimer's Disease: A 24-Month Longitudinal Study.Journal of molecular neuroscience : MN · 2026Article
- The Potential Role of SGLT2 Inhibitors in the Treatment of Depression: Mechanisms and Clinical Prospects.Drug design, development and therapy · 2026Review
- Alteration of fronto-thalamic-striatal and visual network activity to positive emotional stimuli in adolescent patients with bipolar disorder during a Go/No-Go task-based functional brain MRI.NeuroImage. Clinical · 2026Article
- The Potential Anti Stress-like Properties of Escitalopram on Improvement of Spatial Memory in Rats Subjected to Predictable and Unpredictable Chronic Mild Stress.Advanced biomedical research · 2026Article
- SSRIs: exploring controversies, conundrums, and contentions-epiphenomenon or empirical ingenuity? A comparative panorama for untangling enigma in children and youths.CNS spectrums · 2025Review
- The Extract ofInternational journal of molecular sciences · 2025Article
- Cognitive and cerebral phenotypes of neurocognitive disorders due to alcohol or Alzheimer's disease.Brain communications · 2025Article
- Synaptic Interactions Between Serotonergic and Dopaminergic Systems in Parkinson's Disease.Current neuropharmacology · 2025Review
- Concomitant Treatment with Doxycycline and Rifampicin in Balb/c Mice Infected withPharmaceuticals (Basel, Switzerland) · 2024Article
- Protective Effects of Long-Term Escitalopram Administration on Memory and HippocampalBrain sciences · 2024Article
- Serotonin as a biomarker of toxin-induced Parkinsonism.Molecular medicine (Cambridge, Mass.) · 2024Article
- Dialectics of perisomatic inhibition-The unity and conflict of opposites.Frontiers in neural circuits · 2024Review
- Exploring the interplay between running exercises, microbial diversity, and tryptophan metabolism along the microbiota-gut-brain axis.Frontiers in microbiology · 2024Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The hippocampus plays an important role in emotional and cognitive processing, and both of these domains are affected in patients with major depressive disorder (MDD). Extensive preclinical research and the notion that modulation of serotonin (5-HT) neurotransmission plays a key role in the therapeutic efficacy of selective serotonin reuptake inhibitors (SSRIs) support the view that 5-HT is important for hippocampal function in normal and disease-like conditions. The hippocampus is densely innervated by serotonergic fibers, and the majority of 5-HT receptor subtypes are expressed there. Furthermore, hippocampal cells often co-express multiple 5-HT receptor subtypes that can have either complementary or opposing effects on cell function, adding to the complexity of 5-HT neurotransmission. Here we review the current knowledge of how 5-HT, through its various receptor subtypes, modulates hippocampal output and the activity of hippocampal pyramidal cells in rodents. In addition, we discuss the relevance of 5-HT modulation for cognitive processing in rodents and possible clinical implications of these results in patients with MDD. Finally, we review the data on how SSRIs and vortioxetine, an antidepressant with multimodal activity, affect hippocampal function, including cognitive processing, from both a preclinical and clinical perspective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.